The influence of interferon-α on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma

European Journal of Haematology

Volumn 63, Issue 3, 1999, Pages 163-170

  Hassan, Moustapha ^a   Nilsson, Christina ^a   Olsson, Hanna ^b   Lundin, Jeanette ^a   Österborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

4 hydroxycyclophosphamide; Cyclophosphamide; Interferon ; Multiple myeloma; Pharmacokinetics

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ALPHAN1 INTERFERON; CYCLOPHOSPHAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; LEUKOCYTE COUNT; MULTICENTER STUDY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032865199     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01764.x     Document Type: Article

References (37)

1. RICCARDI A, MORA O, BRUGNATELLI S, et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1998;77:485-491.
2. MELLSTEDT H. Cyclophosphamide: lymphoblastoid alfa interferon, betamethsone (CIB) for treatment of newly diagnosed patients with multiple myeloma stages II and III-a phase IB/II trail from the myeloma group of central Sweden. London: Current Medical Literature Ltd; 1995.
3. MOORE MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991;20:194-208.
4. AYASH LJ, WRIGHT JE, TREIYAKOV O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
5. DURKEE C, BENSON R, Jr. Bladder cancer following administration of cyclophosphamide. Urology 1980;16:145-148.
6. LOW JE, BORCH RF, SLADEK NE. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis. Cancer Res 1982;42:830-837.
7. SLADEK NE, POWERS JF, GRAGE GM. Half-life of oxazaphosphorines in biological fluids. Drug Metab Dispos 1984;12:553-559.
8. SLATTERY JT, KALHORN TF, MCDONALD GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-1494.
9. SANDSTROM M, FREUS A, LARSSON R, et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581-1588.
10. STRUCK RF, ALBERTS DS, HORNE K, PHILLIPS JG, PENG YM, ROE DJ. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous vs. oral administration in a randomized, crossover trial. Cancer Res 1987;47:2723-2726.
11. CHANG TK, WEBER GF, CRESPI CL, WAXMAN DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-5637.
12. MOORE MJ, HARDY RW, THIESSEN JJ, SOLDIN SJ, ERLICHMAN C. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988;44:622-628.
13. SCHULER U, EHNINGER G, WAGNER T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol 1987;20:248-252.
14. YULE SM, BODDY AV, COLE M, et al. Cyclophosphamide metabolism in children. Cancer Res 1995;55:803-809.
15. BALKWILL FR, MOWSHOWITZ S, SEILMAN SS, et al. Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drugmetabolizing enzymes. Cancer Res 1984;44:5249-5255.
16. COOPER MR, WELANDER CE. Interferons in the treatment of multiple myeloma. Cancer 1987;59(Suppl):594-600.
17. PEEST D, BLADE J, HAROUSSEAU JI, KLEIN B, OSTERBORG A, SAN MIGUEL JF. Cytokine therapy in multiple myeloma. Br J Haematol 1996;94:425-432.
18. LUDWIG H, COHEN AM, POLLIACK A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995;6:467-476.
19. DURIF BG, CLOUSE L, BRAICH T, GRIMM M, ROBERTONE AB. Interferon alfa-2b-cyclophosphamide combination studies: in vitro and phase I-II clinical results. Semin Oncol 1986;13(Suppl 2):84-88.
20. DURIE BG, SALMON SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
21. HARDY RW, ERLICHMAN C, SOLDIN SJ. High-performance liquid chromatographic measurement of cyclophosphamide in serum. Ther Drug Monit 1984;6:313-318.
22. JOHANSSON M, BIELENSTEIN M. Determination of 4-hydroxycyclophosphamide in plasma, us 2,4- dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography. J Chromatogr B Biomed Appl 1994;660:111-120.
23. OSTERBORG A, BJORKHOLM M, BJOREMAN M, et al. Natural interferon-alpha in combination with melphalan/prednisone vs. melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993;81:1428-1434.
24. COOPER MR, DEAR K, MCINTYRE OR, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993;11:155-160.
25. SLADEK NE, DOEDEN D, POWERS JF, KRIVET W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 1984;68:1247-1254.
26. HONG PS, SRIGRITSANAPOL A, CHAN KK. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat. Drug Metab Dispos 1991;19:1-7.
27. CHEN TL, KENNEDY MJ, ANDERSON LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos 1997;25:544-551.
28. CHANG TK, YU L, MAUREL P, WAXMAN DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57:1946-1954.
29. DELAPORTE E, CRIBB AE, RENTON KE. Modulation of rat hepatic CYP3A1 induction by the interferon inducer polyinosinic acid-polycytidylic acid (polyic). Drug Metab Dispos 1993;21:520-523.
30. ANARI MR, CRIBB AE, RENTON KW. The duration of induction and species influences the downregulation of cytochrome P450 by the interferon inducer polyinosinic acid- polycytidylic acid. Drug Metab Dispos 1995;23:536-541.
31. WILLIAMS SJ, BAIRD-LAMBERT JA, FARRELL GC. Inhibition of theophylline metabolism by interferon. Lancet 1987;2:939-941.
32. LEWIS D. Cytochrome P 450: Structure, function and mechanism. London: Taylor & Francis; 1996.
33. VON EITZEN U, MEIER-TACKMANN D, AGARWAL DP, GOEDDE HW. Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett 1994;76:45-49.
34. BODDY AV, FURTUN Y, SARDAS S, SARDAS O, IDLE JR. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide [see comments]. J Natl Cancer Inst 1992;84:1744-1748.
35. HADIDI AH, COULTER CE, IDLE JR. Phenotypically deficient urinary, elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res 1988;48:5167-5171.
36. YOSHIDA A. Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics 1992;2:139-147.
37. SCHOMBURG A, KIRCHNER H, LOPEZ-HANNINEN E, et al. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy. Am J Clin Oncol 1994;17:199-209.